Letosteine

Letosteine
Clinical data
Trade names	Viscotiol
Other names	2-[2-(ethoxycarbonylmethylsulfanyl)ethyl]-1,3-thiazolidine-4-carboxylic acid
Routes of; administration	Oral (gastroresistant capsules)
ATC code	R05CB09 (WHO) ;
Identifiers
	IUPAC name 2-[2-(2-ethoxy-2-oxoethyl)sulfanylethyl]-1,3-thiazolidine-4-carboxylic acid;
CAS Number	53943-88-7 ;
PubChem CID	68707;
DrugBank	DB08939 ;
ChemSpider	61958 ;
UNII	6MVF9U95DW;
KEGG	D07380 ;
ChEBI	CHEBI:88271 ;
CompTox Dashboard (EPA)	DTXSID70866372 ;
ECHA InfoCard	100.053.509
Chemical and physical data
Formula	C10H17NO4S2
Molar mass	279.37 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)C1NC(SC1)CCSCC(=O)OCC;
	InChI InChI=1S/C10H17NO4S2/c1-2-15-9(12)6-16-4-3-8-11-7(5-17-8)10(13)14/h7-8,11H,2-6H2,1H3,(H,13,14) ; Key:IKOCLISPVJZJEA-UHFFFAOYSA-N ;
	(what is this?) (verify)

Letosteine is a mucolytic^[1] patented (U.S. patent 6987120) by Piero del Soldato of Milan, Italy.^[2] He filed his application in 2000.

^ Zhou Y, Sun S, Liu H, Cui L, Chang X, Sun Z (November 2014). "Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial". Die Pharmazie. 69 (11): 842–9. PMID 25985582.
^ US 6987120, del Soldato P, "Pharmaceutical compounds", issued 17 January 2006, assigned to Nicox SA